178 related articles for article (PubMed ID: 35974705)
1. Evolving utility of apremilast in dermatological disorders for off-label indications.
Mehta H; Sharma A; Dogra S
Clin Exp Dermatol; 2022 Dec; 47(12):2136-2149. PubMed ID: 35974705
[TBL] [Abstract][Full Text] [Related]
2. Off-label studies on apremilast in dermatology: a review.
Maloney NJ; Zhao J; Tegtmeyer K; Lee EY; Cheng K
J Dermatolog Treat; 2020 Mar; 31(2):131-140. PubMed ID: 30935262
[No Abstract] [Full Text] [Related]
3. Apremilast in dermatology: A review of literature.
Nassim D; Alajmi A; Jfri A; Pehr K
Dermatol Ther; 2020 Nov; 33(6):e14261. PubMed ID: 32876993
[TBL] [Abstract][Full Text] [Related]
4. Apremilast Uses and Relevance to the Military.
Hathaway NE; Lyford WH
Cutis; 2021 Apr; 107(4):216-220. PubMed ID: 34096849
[TBL] [Abstract][Full Text] [Related]
5. On- and Off-Label Uses of Apremilast in Dermatology.
Plachouri KM; Georgiou S
Acta Dermatovenerol Croat; 2020 Dec; 28(3):171-179. PubMed ID: 33422172
[TBL] [Abstract][Full Text] [Related]
6. ▼ Apremilast for psoriasis and psoriatic arthritis.
Drug Ther Bull; 2015 Sep; 53(9):105-8. PubMed ID: 26358317
[TBL] [Abstract][Full Text] [Related]
7. Safety evaluation of apremilast for the treatment of psoriasis.
Dattola A; Del Duca E; Saraceno R; Gramiccia T; Bianchi L
Expert Opin Drug Saf; 2017 Mar; 16(3):381-385. PubMed ID: 28132578
[TBL] [Abstract][Full Text] [Related]
8. Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule.
Afra TP; Razmi TM; Dogra S
Indian Dermatol Online J; 2019; 10(1):1-12. PubMed ID: 30775293
[TBL] [Abstract][Full Text] [Related]
9. Apremilast to treat oral ulcers in Behçet syndrome.
Yazici H
Drugs Today (Barc); 2020 May; 56(5):303-310. PubMed ID: 32406877
[TBL] [Abstract][Full Text] [Related]
10. Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.
Metyas S; Tomassian C; Messiah R; Gettas T; Chen C; Quismorio A
Curr Rheumatol Rev; 2019; 15(3):234-237. PubMed ID: 30499418
[TBL] [Abstract][Full Text] [Related]
11. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
Keating GM
Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
[TBL] [Abstract][Full Text] [Related]
12. Drug safety evaluation of apremilast for treating psoriatic arthritis.
Busa S; Kavanaugh A
Expert Opin Drug Saf; 2015 Jun; 14(6):979-85. PubMed ID: 25827658
[TBL] [Abstract][Full Text] [Related]
13. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.
Palfreeman AC; McNamee KE; McCann FE
Drug Des Devel Ther; 2013; 7():201-10. PubMed ID: 23569359
[TBL] [Abstract][Full Text] [Related]
14. Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet's Syndrome.
Mease PJ; Hatemi G; Paris M; Cheng S; Maes P; Zhang W; Shi R; Flower A; Picard H; Stein Gold L
Am J Clin Dermatol; 2023 Sep; 24(5):809-820. PubMed ID: 37316690
[TBL] [Abstract][Full Text] [Related]
15. Apremilast for the management of moderate to severe plaque psoriasis.
Vangipuram R; Alikhan A
Expert Rev Clin Pharmacol; 2017 Apr; 10(4):349-360. PubMed ID: 28276777
[TBL] [Abstract][Full Text] [Related]
16. The Use of Apremilast in Psoriasis: A Delphi Study.
Carrascosa JM; Belinchón I; Rivera R; Ara M; Bustinduy M; Herranz P
Actas Dermosifiliogr (Engl Ed); 2020 Mar; 111(2):115-134. PubMed ID: 31864537
[TBL] [Abstract][Full Text] [Related]
17. Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients: Case report and review of literature.
Garcovich S; Giovanardi G; Malvaso D; De Simone C; Peris K
Medicine (Baltimore); 2020 Jan; 99(5):e18991. PubMed ID: 32000436
[TBL] [Abstract][Full Text] [Related]
18. Off-label studies on tofacitinib in dermatology: a review.
Tegtmeyer K; Zhao J; Maloney NJ; Atassi G; Beestrum M; Lio PA
J Dermatolog Treat; 2021 Jun; 32(4):399-409. PubMed ID: 31581859
[TBL] [Abstract][Full Text] [Related]
19. Apremilast in the treatment of psoriasis and psoriatic arthritis.
Gooderham M; Papp K
Skin Therapy Lett; 2015; 20(5):1-6. PubMed ID: 26382906
[TBL] [Abstract][Full Text] [Related]
20. Apremilast (Otezla). No progress in plaque psoriasis or psoriatic arthritis.
Prescrire Int; 2016 Jun; 25(172):149-51. PubMed ID: 27486641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
